Metuximab binds to the HAb18G/CD147 antigen on the surface of hepatoma cells and blocks HAb18G/CD147 antigen-induced signal transduction pathways, thereby inhibiting the metastasis and invasion of hepatoma cells and reducing liver cancer metastasis and recurrence. The gene discussed is BSG; the disease is liver cancer.